Business
BioSpectrum Asia
JNCASR and CrisprBits to set up CRISPR Centre of Excellence in Innovation and Translation
A Letter of Intent (LOI) has been signed for the establishment of CRISPR Centre of Excellence for Innovation & Translation (CoE-CIT).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Beckman Coulter Life Sciences unveils Biomek i3 Benchtop Liquid Handler
Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, makes liquid handling research more accessible with the launch of the Biomek iz Benchtop Liquid Handler.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chad May steps in as Chief Scientific Officer at Orum Therapeutics
Orum Therapeutics, a biotechnology company based in the US and South Korea, has announced the appointment of Dr Chad May as Chief Scientific Officer (CSO).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
PAHO reviews measles elimination status in United States and Mexico
The Pan American Health Organization (PAHO) Regional Monitoring and Re-Verification Commission for Measles, Rubella, and Congenital Rubella Syndrome (RVC) has invited the United States and Mexico to meet virtually on April 13, 2026, to review their measles elimination status.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
US FDA approves first treatment for children with Menkes Disease
The US Food and Drug Administration (FDA) has approved the Zycubo (copper histidinate) injection, to Sentynl Therapeutics, as the first treatment for Menkes disease in paediatric patients.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
SINGAPORE SHOWS WHAT TARIFFS CAN'T
While U.S. President Donald Trump was publicly defending his threat of higher import tariffs on medicines, Singapore was quietly experiencing an unexpected upside: a surge in pharmaceutical production.
2 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hong Kong designs mucus-inspired hydrogel to boost gastrointestinal wound healing
The Hong Kong Polytechnic University (PolyU) has developed an acid-resistant “ultra-stable mucus-inspired hydrogel” (UMIH), marking a breakthrough in the field of gastrointestinal medicine.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Africa lifts Mpox as Public Health Emergency of Continental Security
Africa has officially lifted Mpox as a Public Health Emergency of Continental Security following recommendations from the Africa CDC Emergency Consultative Group.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Revvity introduces AI-augmented design platform for molecular and materials discovery
US-based Revvity, Inc. has announced the introduction of its forthcoming Signals Xynthetica Models-as-a Service (MaaS) AI offering within the Revvity Signals platform.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Singapore's NUS launches premier Executive Master Programme to shape Asia's digital future
To address the anticipated shortage of leaders capable of turning artificial intelligence (AI) potential into economic reality, the Asian Institute of Digital Finance (AIDF) at the National University of Singapore has officially launched the inaugural Executive Master in Artificial Intelligence and Digital Transformation (EMAI).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Nuevocor names AI Gianchetti as CEO
Singapore-based biotech company Nuevocor has announced the appointment of AI Gianchetti as Chief Executive Officer (CEO) and member of the Board of Directors.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
US announces major policy shift to end use of human foetal tissue
The National Institutes of Health (NIH) in the US has announced a new policy ending the use of human foetal tissue in NIH-supported research, marking a significant milestone in the Trump Administration's efforts to modernise biomedical science and accelerate innovation.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Spider venom drug enters clinical trial in Australia for heart attack, stroke treatment
A potential treatment for heart attack and stroke, derived from a spider venom molecule identified by Australia-based University of Queensland (UQ) researchers, has been administered to the first participants in a clinical trial.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Singapore finds new way to restore healing in chronic wounds
An international team of scientists, led by Nanyang Technological University, Singapore (NTU Singapore), has discovered a new way that could speed up the healing of chronic wounds infected by antibioticresistant bacteria.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Akums signs MoU with Sharda University to strengthen industryacademia collaboration
India-based Akums Drugs & Pharmaceuticals, a contract development and manufacturing organization (CDMO), has signed a Memorandum of Understanding (MoU) with Sharda University, Agra, to foster long-term collaboration in pharmaceutical research, technology transfer, and skill development.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Teoxane opens first APAC regional academy for medical education in Bangkok
Teoxane has opened its first APAC Regional Academy in Bangkok, expanding its global medical-education network.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Novotech appoints Dr Anand Tharmaratnam as new Chief Executive Officer
Novotech, a globally recognized full-service biotech clinical research organisation (CRO) has announced the appointment of D Anand Tharmaratnam as its new Chief Executive Officer (CEO).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
US announces major policy shift to end use of human foetal tissue
The National Institutes of Health (NIH) in the US has announced a new policy ending the use of human foetal tissue in NIH-supported research, marking a significant milestone in the Trump Administration's efforts to modernise biomedical science and accelerate innovation.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
ErlySign ropes in Vishal Kumar as Vice President Business
ErlySign, a biotech startup developing India's first salivary biomarker-based screening test for early-stage oral cancer, has announced the appointment of Vishal Kumar as Vice President - Business.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
World Bank Supports improved health services in Salvador
The World Bank Board of Directors has approved a new operation to expand access to quality health, education, and social assistance services in Brazil's Municipality of Salvador, in the northeastern State of Bahia.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leadgene Biosolutions expands product portfolio for metabolic research
Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Korea, Philippines to develop nextgeneration tuberculosis diagnosis
The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia and Indonesia achieve WHO Listed Authority status in medical products regulation
The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Aevice Health announces expansion into Australian market
AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO
Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia provides cheaper medicines for inflammatory & rare liver disease and MS
Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement
France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal
Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy
Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hyphens Pharma outlicences Cerapro MED to 6 European countries
Singapore-based Hyphens Pharma International has granted the rights to commercialise its innovative product, Cerapro MED Skin Barrier Cream, to Louis Widmer SA via a licensing, supply and commercialisation agreement that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.
1 min |